ImmunityBio Inc. (NASDAQ:IBRX) saw a 7.76% increase in stock value after receiving approval from the European Medicines Agency (EMA) to sell its bladder cancer treatment Anktiva in Europe. Anktiva, in combination with Bacillus Calmette-Guerin (BCG), is authorized for the treatment of non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. This approval allows the company to expand its sales and operations in Europe. Unlike the US, Europe recognizes approximately six major BCG substrains, making standard-of-care therapy more widely available across the region. ImmunityBio Inc. (NASDAQ:IBRX) Executive Chairman Patrick Soon-Shiong expressed excitement about the positive recommendation from the EMA, emphasizing the benefits of Anktiva in improving the immune response and durability of BCG therapy.

Read more at Yahoo Finance: ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion